Kisspeptin-10 vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Kisspeptin-10
Kisspeptin-10 is the active fragment of kisspeptin, a hormone that plays a crucial role in initiating puberty and regulating reproductive function. It acts upstream of GnRH in the hypothalamic-pituitary-gonadal axis.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Kisspeptin-10 | Tesamorelin |
|---|---|---|
| Dose Range | 100 mcg–1 mg | 2 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to KISS1R receptors in the hypothalamus, stimulating GnRH neurons to release GnRH. This triggers the downstream cascade of LH, FSH, and sex hormone production. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Research protocols vary widely. Studies have used IV boluses of 1-10mcg/kg or subcutaneous administration. Clinical applications still being developed. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | IV or subcutaneous injection. Has very short half-life requiring frequent administration or continuous infusion for sustained effects. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Limited data. May cause flushing, increased heart rate, and changes in libido. Generally well-tolerated in studies. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
Key Differences
Unique to Kisspeptin-10:
Unique to Tesamorelin:
Key Studies
Kisspeptin-10
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.
European journal of endocrinology, 2026
- Kisspeptin-10 Protects Against TNF-α-Induced Chondrocyte Senescence via the SIRT1/p53/p21 Signaling.
Journal of biochemical and molecular toxicology, 2025
- Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice.
Biomolecules, 2025
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?